Individualised Multimodal Treatment Strategies for Anaplastic and Poorly Differentiated Thyroid Cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Individualised Multimodal Treatment Strategies for Anaplastic and Poorly Differentiated Thyroid Cancer
Authors
Keywords
-
Journal
Journal of Clinical Medicine
Volume 7, Issue 5, Pages 115
Publisher
MDPI AG
Online
2018-05-15
DOI
10.3390/jcm7050115
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Epigenetic modifications in poorly differentiated and anaplastic thyroid cancer
- (2018) Thanyawat Sasanakietkul et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Epigenetic Modifications in Thyroid Cancer Cells Restore NIS and Radio-Iodine Uptake and Promote Cell Death
- (2018) Sabine Wächter et al. Journal of Clinical Medicine
- Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy
- (2017) Chae Moon Hong et al. Frontiers in Endocrinology
- Treatment of advanced thyroid cancer with targeted therapies: ten years of experience
- (2016) David Viola et al. ENDOCRINE-RELATED CANCER
- MicroRNAs let7 expression in thyroid cancer: correlation with their deputed targets HMGA2 and SLC5A5
- (2016) Alexander I. Damanakis et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Inhibition of miR-146b expression increases radioiodine-sensitivity in poorly differential thyroid carcinoma via positively regulating NIS expression
- (2015) Luchuan Li et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- MiR-146b-5p Promotes Metastasis and Induces Epithelial-Mesenchymal Transition in Thyroid Cancer by Targeting ZNRF3
- (2015) Xianzhao Deng et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- In Situ Hybridization Analysis of miR-146b-5p and miR-21 in Thyroid Nodules: Diagnostic Implications
- (2015) Zhenying Guo et al. ENDOCRINE PATHOLOGY
- Integrated Genomic Characterization of Papillary Thyroid Carcinoma
- (2014) Nishant Agrawal et al. CELL
- microRNA-339-5p modulates Na+/I− symporter-mediated radioiodide uptake
- (2014) Aparna Lakshmanan et al. ENDOCRINE-RELATED CANCER
- Effects of let-7 microRNA on Cell Growth and Differentiation of Papillary Thyroid Cancer
- (2014) Jølio Cezar Marques et al. Translational Oncology
- MicroRNA Deregulation in Anaplastic Thyroid Cancer Biology
- (2014) Cesar Seigi Fuziwara et al. International Journal of Endocrinology
- MicroRNAs miR-146-5p and let-7f as prognostic tools for aggressive papillary thyroid carcinoma: a case report
- (2013) Murilo Vieira Geraldo et al. Arquivos Brasileiros de Endocrinologia e Metabologia
- Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer
- (2013) Daniel Chan et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- In-Depth Characterization of the MicroRNA Transcriptome in Normal Thyroid and Papillary Thyroid Carcinoma
- (2013) Michal Swierniak et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
- (2013) Alan L. Ho et al. NEW ENGLAND JOURNAL OF MEDICINE
- Histone Deacetylase Inhibition Affects Sodium Iodide Symporter Expression and Induces 131I Cytotoxicity in Anaplastic Thyroid Cancer Cells
- (2013) Mariateresa Pugliese et al. THYROID
- Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines
- (2012) Pietro Di Fazio et al. EXPERIMENTAL CELL RESEARCH
- Prognostic Implications of miR-146b Expression and Its Functional Role in Papillary Thyroid Carcinoma
- (2012) Chen-Kai Chou et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo
- (2011) Maria Graziella Catalano et al. INTERNATIONAL JOURNAL OF CANCER
- Anaplastic Thyroid Cancer: A Review of Epidemiology, Pathogenesis, and Treatment
- (2011) Govardhanan Nagaiah et al. Journal of Oncology
- The pan-DAC inhibitor LBH589 is a multi-functional agent in breast cancer cells: cytotoxic drug and inducer of sodium-iodide symporter (NIS)
- (2010) N. Fortunati et al. BREAST CANCER RESEARCH AND TREATMENT
- HMGA2: A pituitary tumour subtype-specific oncogene?
- (2010) Monica Fedele et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started